Country comparison
CAR-T in China vs Australia
7 min read · Last verified: 2026-09-09
How CAR-T access works in Australia
Australia funds CAR-T through joint Commonwealth–state agreements for high-cost, highly specialised therapies, decided after review by the Medical Services Advisory Committee (MSAC) — not through a standard PBS listing. Each product and indication arrives separately, and delivery is limited to a small number of accredited hospitals, mostly in state capitals.
Funded as of September 2026:
- Tisagenlecleucel (Kymriah) for B-cell acute lymphoblastic leukaemia in patients up to 25 (federal funding announced 2022).
- Kymriah and axicabtagene ciloleucel (Yescarta) for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy.
- Brexucabtagene autoleucel (Tecartus) for relapsed or refractory mantle cell lymphoma (publicly funded from early 2024, initially at the Alfred, Royal Prince Alfred, Peter MacCallum and Westmead hospitals).
- Ciltacabtagene autoleucel (Carvykti) for myeloma after at least four prior lines of therapy — announced 5 May 2026, initially only at Alfred Health and Peter MacCallum in Victoria, with other states activating as agreements are signed (Myeloma Australia).
Two features define the Australian reality. First, access is geographically uneven: criteria are national, but states activate at different speeds, and patients may need to relocate for weeks — Carvykti recipients currently relocate to Melbourne for at least four weeks. Second, as Myeloma Australia states plainly, there is no option to self-fund — Australia has no private-pay CAR-T pathway.
When Australian patients look at China
- They do not meet the funded criteria. A myeloma patient with fewer than four prior lines, a subtype outside the funded list, or a disease state that cannot wait for the next agreement to be signed.
- Their state is not activated yet. A Victoria-first rollout is cold comfort in Perth or Brisbane when the disease is moving.
- They want an option Australia has no pathway for. Because self-funding at home is not available, paying abroad is the only way to pay at all.
A complete China journey typically totals $170,000–260,000, with product list prices of $140,000–180,000 (site dataset, NMPA list prices, verified 2026-07). See the itemized cost page.
The honest trade-offs
If you meet the funded criteria and your state can treat you, stay home. Fully funded CAR-T with Medicare-backed follow-up is the strongest position a patient can be in; no self-paid journey improves on it.
If you travel: six to ten weeks away, the highest-risk days straight after infusion spent far from your team, and a follow-up handoff your Australian haematologist must agree to accept. Discuss it with them before committing, including who manages late complications once you are back. And weigh the wait honestly in both directions: months spent waiting for local access carry a clinical cost, but so does boarding a long flight in the weeks after CAR-T.
Questions to ask your treating team
- Do I meet the funded criteria for my diagnosis — and is my state actually delivering it now?
- If not, is a clinical trial open to me here?
- If I self-fund overseas, will you manage my follow-up, and what records would you need?
- In my case, what is the clinical cost of waiting versus travelling?
Where to go next
Sources
Compare with another country